Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?


Journal

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
ISSN: 1559-7016
Titre abrégé: J Cereb Blood Flow Metab
Pays: United States
ID NLM: 8112566

Informations de publication

Date de publication:
01 2022
Historique:
pubmed: 10 9 2021
medline: 9 2 2022
entrez: 9 9 2021
Statut: ppublish

Résumé

Only partial deficiency/inhibition of P-glycoprotein (P-gp, ABCB1) function at the blood-brain barrier (BBB) is likely to occur in pathophysiological situations or drug-drug interactions. This raises questions regarding the sensitivity of available PET imaging probes to detect moderate changes in P-gp function at the living BBB.

Identifiants

pubmed: 34496661
doi: 10.1177/0271678X211045444
pmc: PMC8721783
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B 0
Carbon Radioisotopes 0
Radiopharmaceuticals 0
multidrug resistance protein 3 9EI49ZU76O

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-185

Références

Curr Pharm Des. 2016;22(38):5779-5785
pubmed: 27568733
Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
J Nucl Med. 2020 Jul;61(7):1050-1057
pubmed: 31806767
Eur J Clin Pharmacol. 2009 Sep;65(9):941-6
pubmed: 19655132
J Cereb Blood Flow Metab. 2007 Feb;27(2):424-33
pubmed: 16757979
J Nucl Med. 2009 Aug;50(8):1267-75
pubmed: 19617341
Clin Pharmacol Ther. 2009 Oct;86(4):368-77
pubmed: 19625998
Clin Pharmacol Ther. 2013 Jul;94(1):80-94
pubmed: 23588303
Neuropharmacology. 2007 Feb;52(2):333-46
pubmed: 17045309
J Cereb Blood Flow Metab. 2015 May;35(5):743-6
pubmed: 25669913
J Med Chem. 2008 Oct 9;51(19):6034-43
pubmed: 18783208
Eur J Pharm Sci. 2016 Aug 25;91:98-104
pubmed: 27283486
Clin Pharmacol Ther. 2021 Mar;109(3):754-761
pubmed: 32966590
J Nucl Med. 2019 Jul;60(7):985-991
pubmed: 30630940
J Nucl Med. 2008 Aug;49(8):1328-35
pubmed: 18632828
J Cereb Blood Flow Metab. 2010 Mar;30(3):510-5
pubmed: 20010957
Clin Pharmacol Ther. 2019 May;105(5):1061-1064
pubmed: 30903694
Drug Metab Dispos. 2008 Feb;36(2):268-75
pubmed: 17962372
Nat Rev Neurosci. 2005 Aug;6(8):591-602
pubmed: 16025095
EJNMMI Res. 2012 Oct 16;2(1):58
pubmed: 23072492
J Nucl Med. 2018 Oct;59(10):1609-1615
pubmed: 29748235
Pharmacol Ther. 2018 Sep;189:104-122
pubmed: 29684469
J Neurochem. 2011 Apr;117(2):333-45
pubmed: 21291474
Pharmacol Ther. 2020 Sep;213:107554
pubmed: 32320731
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2593-8
pubmed: 21262843
Ann Nucl Med. 2013 Aug;27(7):618-24
pubmed: 23572210
J Bioenerg Biomembr. 2007 Dec;39(5-6):481-7
pubmed: 18058211
N Engl J Med. 2020 Aug 20;383(8):787-789
pubmed: 32813957
J Nucl Med. 2010 Apr;51(4):559-66
pubmed: 20237038
J Control Release. 2018 Dec 28;292:210-220
pubmed: 30415015
Toxicol Appl Pharmacol. 1997 Sep;146(1):88-94
pubmed: 9299600
J Nucl Med. 2016 Feb;57(2):309-14
pubmed: 26585058
Nucl Med Biol. 2005 Jan;32(1):87-93
pubmed: 15691665
Trends Pharmacol Sci. 2009 Aug;30(8):431-40
pubmed: 19616318
Mol Pharm. 2019 Mar 4;16(3):1282-1293
pubmed: 30694684
Pharm Res. 2009 Aug;26(8):1816-31
pubmed: 19421845
Pharmacol Ther. 2009 Jul;123(1):80-104
pubmed: 19393264
Pharm Res. 2012 Sep;29(9):2468-76
pubmed: 22644589
Clin Pharmacol Ther. 2005 Jun;77(6):503-14
pubmed: 15961982
Mol Pharm. 2015 Sep 8;12(9):3214-25
pubmed: 26202880
Mol Pharm. 2011 Aug 1;8(4):1332-41
pubmed: 21707071
J Cereb Blood Flow Metab. 2000 Feb;20(2):381-6
pubmed: 10698076
Epilepsia. 2010 Sep;51(9):1780-90
pubmed: 20633036
Curr Pharm Des. 2016;22(38):5786-5792
pubmed: 27494063
Brain. 2012 Oct;135(Pt 10):3115-33
pubmed: 22750659
Mol Pharm. 2020 Sep 8;17(9):3477-3486
pubmed: 32787277
Drug Metab Dispos. 2005 Jan;33(1):165-74
pubmed: 15502009
Biochim Biophys Acta. 2014 Nov;1838(11):2882-98
pubmed: 25068895
J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):68-77
pubmed: 24285312
Contrast Media Mol Imaging. 2018 May 8;2018:7310146
pubmed: 29853808
Clin Pharmacol Ther. 2012 Feb;91(2):227-33
pubmed: 22166851
J Nucl Med. 2015 Jan;56(1):82-7
pubmed: 25500831
Br J Clin Pharmacol. 2017 Sep;83(9):1991-1999
pubmed: 28401570

Auteurs

Louise Breuil (L)

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay France.
Pharmacy Department, Robert-Debré Hospital, AP-HP, Université de Paris, Paris, France.

Solène Marie (S)

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay France.
Pharmacy Department, Bicêtre Hospital, AP-HP, Université Paris-Saclay, Le Kremlin-Bicêtre, France.

Sébastien Goutal (S)

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay France.

Sylvain Auvity (S)

Pharmacy Department, Necker Hospital, AP-HP, UMR-S 1144, Université de Paris, Paris, France.

Charles Truillet (C)

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay France.

Wadad Saba (W)

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay France.

Oliver Langer (O)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Fabien Caillé (F)

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay France.

Nicolas Tournier (N)

Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH